Scientists have developed a new genetic fingerprint test which aims to identify women with breast cancer who are likely to respond to a class of often-useful, but toxic chemotherapy agents including one commonly referred to as “the red devil” by patients and survivors.
New DNA “Fingerprint” Test Predicts Response To Toxic Breast Cancer Drugs
